Background: Glioblastoma (GBM) represents the most prevalent primary malignant brain tumor. Temozolomide (TMZ) is the primary chemotherapeutic agent administered following surgical resection. However, the emergence of TMZ resistance in patients undergoing chemotherapy significantly diminishes its efficacy. To date, the majority of preclinical studies have been unsuccessful in effectively overcoming TMZ resistance. Prior research has suggested that the KIF4A gene may serve as a prognostic indicator for patients with GBM. Nevertheless, the precise mechanism by which KIF4A contributes to TMZ resistance remains to be elucidated. Methods: In order to simulate the in vivo growth environment of glioblastoma, transwell co‐culture and hypoxia induction were employed. Functional experiments were then conducted in order to verify the effects of KIF4A and HIF1A on the proliferation, migration, invasion, and angiogenic ability of GBM cells. Western blot analysis was employed to determine the protein levels of KIF4A, HIF1A, and VEGFA in GBM cells. ELISA was employed to determine the secreted protein levels of VEGFA and MMP9 in GBM cells. A prognostic model was utilized to assess the clinical utility of the pathway. The intercellular resistance to temozolomide was determined through the use of colony formation assays, flow cytometry, and immunofluorescence. The intercellular communication medium and its mechanism were analyzed by electron microscopy, particle size measurement, and WB experiments. Finally, a xenograft tumor model was utilized to investigate the in vivo function of KIF4A. Results: KIF4A promotes the malignant progression of glioblastoma by regulating the HIF1A/VEGFA axis. GBM cells secrete exosomes to regulate the temozolomide resistance of astrocytes and the expression level of HIF1A/VEGFA protein, thereby making glioblastoma more resistant. Conclusion: This study provides a new idea for antagonizing temozolomide resistance in glioblastoma. KIF4A promotes malignant progression of glioblastoma and transmission of TMZ resistance in the tumor microenvironment through the HIF1A/VEGFA axis.
BackgroundDyslipidemia is a common comorbidity in patients with cancer, yet the impact of abnormal lipid levels on tumor prognosis remains contentious. This study was conducted to synthesize the current evidence regarding the prognostic utility of blood lipid levels, including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB), in predicting overall survival (OS) and disease-free survival (DFS) in cancer patients.MethodsA comprehensive literature search was performed across electronic databases to assess the associations between blood lipid levels and OS or DFS in cancer patients. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to analyze the data. The research protocol was previously submitted to the International Prospective Register of Systematic Reviews (PROSPERO): CRD42023458597.ResultsOur study represents the largest and most extensive evaluation of the prognostic significance of blood lipid levels in cancer to date. It includes a meta-analysis of 156 eligible studies involving 85,173 cancer patients. The findings revealed a significant association between elevated levels of HDL-C, TC, and ApoA1 and improved OS and DFS in cancer patients. In contrast, no significant relationships were identified between LDL-C, TG, and ApoB levels and the OS or DFS of cancer patients.ConclusionBlood lipids, particularly HDL-C, TC, and ApoA1, emerge as accessible and cost-effective biomarkers that may aid in assessing survival outcomes in cancer patients and potentially inform clinical decision-making.
Background: Digestive system cancers (DSCs) have been recognized to be linked with high morbidity and mortality. Recent studies have reported that microRNA-10b (miR-10b) is abnormally expressed in DSCs and associated with prognosis. However, the inconclusive results and unknown underlying mechanisms promoted us to perform this study.
11 June 2025 in Clinical and Translational Oncology
The benefit of adjuvant chemoradiotherapy (CRT) for pancreatic adenocarcinoma (PAAD) is debated. This study aimed to elucidate the impact of adjuvant CRT o